scholarly article | Q13442814 |
P356 | DOI | 10.1016/S1473-3099(19)30611-5 |
P698 | PubMed publication ID | 32275867 |
P50 | author | R. Kiplin Guy | Q67426629 |
P2093 | author name string | Li Tang | |
John C Panetta | |||
Amber M Smith | |||
James S McCarthy | |||
Patricia M Flynn | |||
Jörg J Möhrle | |||
Burgess B Freeman | |||
Aditya H Gaur | |||
Robbin Christensen | |||
Yvonne Van Gessel | |||
Fabian Gusovsky | |||
Branko Mitasev | |||
Elizabeth John | |||
Stephan Chalon | |||
Ronald H Dallas | |||
John Woodford | |||
Lidiya Bebrevska | |||
Julie L Richardson | |||
Kristen C Branum | |||
Nehali D Patel | |||
Ryan N Heine | |||
Shelley Ost | |||
Tracy B Stewart | |||
P2860 | cites work | New developments in anti-malarial target candidate and product profiles | Q28468598 |
A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs | Q28476638 | ||
Chemical genetics of Plasmodium falciparum | Q29617272 | ||
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. | Q30610467 | ||
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study | Q33732740 | ||
Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors | Q33939069 | ||
Spiroindolone KAE609 for falciparum and vivax malaria | Q34085717 | ||
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteer | Q34298776 | ||
Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia. | Q37003081 | ||
Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers | Q37193141 | ||
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study | Q37254756 | ||
Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria | Q37613014 | ||
Malaria medicines: a glass half full? | Q38497838 | ||
A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers | Q41832478 | ||
The global fight against malaria is at crossroads | Q48018228 | ||
The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study | Q50048765 | ||
A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model | Q50318730 | ||
Influenza Virus Infection Model With Density Dependence Supports Biphasic Viral Decay | Q56000676 | ||
P921 | main subject | malaria | Q12156 |
Plasmodium falciparum | Q311383 | ||
pharmacokinetics | Q323936 | ||
P577 | publication date | 2020-04-07 | |
P1433 | published in | Lancet Infectious Diseases | Q15724248 |
P1476 | title | Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial |
Q91807435 | Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin? |
Q104617066 | Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection |
Search more.